*Review Article*

**Corresponding Author:**

∗ Pramod Singh Khatri

Head of Department &
Programme Coordinator,
Clinical Research,
Amity Medical School,
Amity University ,
Haryana, India.

QR Code AJPTI

*Email Id-
**pramodsinghkhatri@gmail.com**

# Stem Cells Therapy: An Innovative Slant in Drug Discovery Research

Pramod Singh Khatri[1], Major General Mahavir Singh[2]

**ABSTRACT**

The recognizable proof of ordinary and carcinogenic stem cell and the latest developments made in seclusion and principles of stem cells have quickly picked up consideration in the field of medicine discovery and regenerative prescriptions. The possibility of performing screens pointed at burgeoning, controlled separation, and toxicity and adequacy studies utilizing stem cells offers a solid stage for the medication finding process. Progresses made in the era of incited pluripotent stem cells from typical or unhealthy tissue serves as a stage to perform medicine screens pointed at creating cell-based treatments against disorders like Parkinson's ailment and diabetes. This review talks about the provision of stem cells and cancer stem cell in medicine screening and their part in supplementing, decreasing, and reinstating animal testing. Notwithstanding this, target distinguishing proof and real developments in the field of customized Medicine utilizing affected pluripotent cells are additionally examined.

**Key-words:** Stem cell Therapy, cancer, drug development, HTS.

1 HOD, Clinical Research, Amity Medical School, Amity University, Haryana, India.

2 HOI, Amity Medical School, Amity University, Haryana, India.

**Introduction**

The appearance of engineering and a plenty of trial work have unequivocally settled the presence of stem cells in numerous tissues (Lebaron et al, 2010). Cell reviving toward oneself, i.e., the capability to handle an indistinguishable duplicate of itself, and multipotency, i.e., the capacity to produce cells not the same as itself, are key qualities of a stem cell. The capability to self-reestablish or be multipotent differs between diverse stem cell and is alluded to as "stemness". These are special qualities that have permitted both the scholarly world and industry to predict the requisition of stem cells in different infections/issue and therapeutic tests, in the same way as Parkinson's illness, Alzheimer's malady, and diabetes, numerous sclerosis, coronary illness, cancer, spinal cord damage, wound recuperating, and organ transplantation.  Recent developments in the medicine of joining versus host sickness and the accomplishment of hematopoietic stem cell transplants have made it conceivable to imagine stem cells as a potential store to help.

Notwithstanding the wide show of requisitions in the field of regenerative drug, the likelihood of performing high-substance medication screens and additionally lethality and adequacy studies has empowered stem cells to turn into a profitable asset in the field of medicine finding and pharmaceutical research (Smith et al, 2007). The latest showing of reprogramming of substantial cells into "embryonic stem cell like" incited pluripotent stem cell has upset pharmaceutical research by connecting human sickness, subject specificity, and medication finding (Fig.1). This procedure couldn't just prompt the advancement of different cell therapies; additionally push the limits of customized drugs.



*Fig 1 cultivation of stem cell from embryo*

**In vitro models of Stem Cell for medication disclosure**

Medication testing utilizing in vitro models has been a real help in recognizing potential remedial mixes, as well as in expanding our understanding of their ingestion, dissemination, digestion system, and discharge (ADME) properties(Gosai et al,2010).  The development of different in vitro ADME models has made an acceptable effect on the pathway towards modernizing and quickening medicine finding and advancement. An agreeable confirmation of standard might be seen on account of terfenadine in the

late1980s, whereby utilization of an in vitro ADME framework empowered scientists to comprehend torsadesde pointes, a regularly lethal cardiovascular arrhythmia. Tumor-inferred or built deified cells acquired from human (or animal) sources have been the most widely recognized in vitro models utilized by the biotechnology and pharmaceutical commercial ventures. While these cell lines have the focal points of accommodation and adaptability of the screening procedure, they indicate high variability in their development, unusual genotype, and physiological reaction to medicines. The irregularities connected with these deified cells limit the trust esteem and number of lead particles for medication development (Laustrait et al,2010). The utilization of particular essential primary models like hepatocytes, human umbilical endothelial cells, and keratinocytes offer restricted use because of their limited expandability (Fig.2).



*Fig 2. Steps for Generation of human embryonic stem cell (hESC).*

The need for an enhanced and uniform physiological reaction, ordinary genotype, and development design has redirected medication finding deliberations towards stem cells. The likelihood of separating stem cell from a wide range of tissues and developing them in vitro, and their capability to separate into various specific cell sorts has given an important apparatus to medication/target finding and validation.

The utilization of stem cell won't just cut medicine finding expenses down, additionally enhance the shots of recognizing leads with a target or pathway applicable to the malady process and with a stronger potential for interpretation to clinical settings (Thorne et al, 2010).

In spite of the fact that stem cell offer colossal potential in the arena of pharmaceutical research, their quick materialness in the field of medicine revelation is constrained because of a mixture of components. Case in point, stem cell from distinctive tissues are not the same, and in vitro culture where the stem cells are overflowed with development elements is unique in relation to the microenvironment in which stem cells dwell in vivo(Gharaee –kermani et al,2007). Stem cells have a slower cell cycle than their begetter cells in vivo, so the level of affectability of readouts acquired in vitro may not be the same as in vivo. Stem cells separated from tissues, for example, the liver, muscle, and fat tissue have a restricted capability to

extend when contrasted with bone marrow-inferred mesenchymal stem cell. Likewise, stem cells inferred from tissues like muscle and the liver lose their possibility to separate upon rehashed extension, while stem hematopoietic stem cell stretch inadequately however can separate into numerous types of platelets (Zambrowicz et al, 2010).

Bone marrow-inferred mesenchymal stem cell offers an alluring high throughput screening stage for new target/ drug finding. These stem cells could be promptly stretched in vitro and might be detached from a mixture of tissue sources, for example, brain, lung, heart, muscle, and the umbilical cord. Bone marrow-determined mesenchymal stem cells have showed versatility for medicine screens and might be separated into neurons, adipocytes, muscle cells, chondrocytes, and osteocytes (Tremblay et al, 2005). These characteristics of bone marrow-determined mesenchymal stem cells permit medication screens to be administered towards stem cell rebuilding toward oneself, expansion, separation, and a mixture of illness related medicine disclosure programs, e.g., for tumor, corpulence, diabetes, and focal or fringe sensory system issue . The correct force of stem cells in medicine finding projects will be completely acknowledged when a promptly expandable assorted board of stem cells gets accessible (Gunawardena et al, 2003).

**Tumor stem cells in medication disclosure:**

Cancerous cells likewise misuse the same properties of toward oneself replenishment and multipotency that make stem cell so engaging in regenerative pharmaceutical and medicine finding. Latest studies have recognized a little extraordinary populace of cells known as cancer stem cells, or tumor-prompting cells that dwell in tumors (Jiang et al, 2010).

These cells emerge from oncogenic change of either stem cells or forebear cells. Cancer stem cells or tumor-affecting cells have "stem-like" character, a moderate multiplication rate, a high limit for recharging toward oneself, imperviousness to standard compound/radiation treatment, and an inclination to separate into earnestly expanding tumor cells(Fig.3). Cancer stem cells have been secluded from numerous tumor sorts, including cerebrum, renal, colon, and prostate tumors, and in addition hematopoietic diseases, and restorative techniques are, no doubt created to target disease stem cell for apoptosis or cell cycle capture particularly and along these lines destroy tumors more viably than flow medicines(Amore et al,2010). Cancer drug revelation projects have, to a vast degree, utilized deified cell lines or essential tumor tissue for in vitro assay. This methodology has been generally unsuitable in creating successful therapeutics for cancer. Tumor drug revelation projects including cancer stem cells as a stage offer a disclosure process with a high level of restorative efficiency (Nirmalanandhan et al, 2009).

*Fig 3. Possible treatment targeting cancer stem cells.*

This is especially clear from the medicine finding process in leukemia (Link et al, 2000). The way that cancer stem cells encourage the cancer development and elevate imperviousness to existing chemotherapeutic medications makes them applicant cells for medicine disclosure screens. In cancer of the hematopoietic framework, cancer stem cell have been overall described in chronic myelogenous leukemia(CML), acute myelogenous leukemia(AML), and acute lymphoblastic leukemia(ALL). Drug finding projects focusing on CD33 in acute myelogenous leukemia and the ABL kinase inhibitor, imatinib mesylate, in chronic myelogenous leukemia have been extremely viable (Mimeault et al, 2006).

From the point of view of medicine revelation and translational research, cancer stem cell furnish a strong stage with critical suggestions for planning restorative methodologies and creating long haul medication(Danovi et al,2010) .It must be noted that in vitro engendering of tumor stem cells does not copy components representing the microenvironment of cancer stem cells, for example, hypoxia, however they do offer a stage for assessing medicine screens with a higher level of trust, consequently encouraging preclinical trials and clinical trials of antitumor therapies. Research reports showing that cancer stem cell might be specifically focused without hurting ordinary stem cells offers a plausibility to perform focused on medicine finding screens against cancer stem cells from diverse tumors.

**Animal model of Stem cell for medication finding**

Stem cells have generally accepted colossal consideration for their potential in refining medicine screens. Stem cell screens are a more practical technique than animal testing. They are additionally seen as a procedure of refining, lessening, and possibly displacing animal testing methods (Fig.4). Nonetheless, animal models offer an entire framework setup for testing the impacts and symptoms of medications. It must be noted that the reaction to medications in animal models may not be the same as in human (Bujan et al, 2006). Animal models vary from those in human in various ways. Specifically, they don't reflect the ethnic assorted qualities of human and their reaction to medications may be distinctive to that seen in human. Likewise, animal models are expensive and prolonged. Stem cells offer an interchange stage to beat the constraints of ethnic differences, give a uniform reaction to a medicine which can connect with the human reaction, and are expense and time-powerful. Shockingly, the flow status of stem cell research does not permit us to substitute for entire animal testing, as seen with animal models. Be that as it may, stem cells are extremely guaranteeing substitutes regarding single organ toxicity. Embryonic or adult

tissue-particular stem cell that can eventually be developed into a whole human organ will be a highest level for single organ medicine testing (Ishizaki et al, 1996).

Cell-based in vitro examines give a framework to perform high throughput or high substance screens, however they don't reflect the unpredictable in vivo situation. Cell-based screens don't think seriously about the cross-talk between organs (or diverse cell sorts) or the general digestion system and symptoms seen in vivo (Lang et al, 1990). Henceforth in vitro measures must be supplemented with different in vivo tests utilizing distinctive animal models. Right now, different invertebrate and vertebrate models are accessible for screening the lethality and viability of lead particles (Giacomotto et al, 2010).



*Fig 4.Animal Model for drug discovery.*

Invertebrate models of Drosophila and Caenorhabditis elegans offer an effective model suitable for medicine finding research. Their little size, short era time, generally minimal effort of lodging and upkeep, very moderated sub-atomic pathways, and accessibility of different hereditary and biochemical instruments have made it conceivable to incorporate them in multistep medicine screening techniques (Jorefezuk et al ,2011). The simplicity with which transgenic, overexpression, and change of proteins is possible, and the moderately basic hereditary course included have empowered their utilization in performing screens administered against Alzheimer's illness, Huntington's malady, oncogenic conversion, stem cell specialty, metastases, neurodegeneration, apoptosis, and behavioral investigates. These basic models offer a setup whereby a specific process, for example, neurodegeneration might be immediately screened. Case in point, a Drosophila Huntington's ailment model and transgenic line give a perfect in vivo framework for not just looking at mutant Huntington gene-intervened cell imperfections, for example, debilitation of axonal transport, additionally encourage fast tests for screening and accepting potential medication to ease the watched cell deformities. The moderately basic metabolic and hereditary falls and the long evolutionary division from human are significant burdens constraining the utilization of these models in medicine development research (Yamazaki et al, 2009).

Higher vertebrate models, for example, rabbits, pooches, monkeys, and rodents have been broadly utilized as a part of medication safety testing. Around them, rodents are a great supplement to stem cell based screening. The accessibility of knockins, contingent knockouts, and transgenic models structures a capable help supportive network to assess the in vivo reaction of different lead atoms distinguished in stem cell situated in vitro screens(Chia et al,2010). The recognizable proof of a tissue-particular stem cell specialty in rat models offers the preference of creating screens coordinated towards control of the stem

cell microenvironment to support in understanding and creating helpful methods for different illnesses, for example, neurodegenerative issue, stroke, organ transplant, mind trauma, wound mending, and cancer. Such screens have recognized molecules that influence the begetter pool size of the grown-up neural stem cell populace.  However, the conventional strategies for examination in rat models are moderate and depend widely on investigates of tissues gathered from relinquished animals (Dhawan et al, 2005).

As of latest, teleost vertebrate models, specifically zebra fish and medaka have gotten prevalent models for contemplating different parts of developmental science and heredity. Their fast outside improvement, transparency of fetuses, cultivation, and vast sample size are a percentage of the preferences promptly offered by these models. The likelihood of performing toxicity and viability screening of chemicals, pharmaceuticals, and pesticides that might be connected as far as human wellbeing risks are driving this model as a decision for toxicological or pharmacological screens. Little molecule screening to distinguish and describe a particle that prepares particular impacts against different infection forms in human has been effectively created (Tickoo et al, 2002).  The zebra fish (Danio rerio) has been more widely utilized than the medaka (Oriyzas latipes), yet both show a high level of anatomical and physiological homology with that of other higher order vertebrates, and additionally have fundamentally the same cell structure, indicating methods, and cognitive conduct(Schaffler et al,2007).

The gathering of different mutant lines with deformities in the development and function of the different metabolic methodologies, and the accessibility of different biochemical, atomic, and hereditary techniques has encouraged the advancement of different in vivo medicine screens focusing on improvement, digestion system, and physiological conditions in view of different human illnesses.

**Target identification and assessment devices supporting stem cell based medication discovery**

Drug finding screens utilizing stem cell are another and monstrously essential asset. The most usually utilized screening procedure includes developing cells as a monolayer culture and lying open them to libraries of new compound substances. The last readout in the vast majority of the high throughput situations is dependent upon imaging. Imaging-based screens are brisk and could be mechanized without lifting a finger. Time-slip tests can likewise be performed to comprehend the onset of the phenotype. Imaging-based readouts can basically utilize brilliant field pictures to comprehend the effect of the compound on colony size, morphology, expansion, and cell number (Abdullah et al, 2009). These picture based readouts can additionally be consolidated with immunofluorescence to test the representation/ hindrance of markers of interest. Economically accessible tests, which utilize fluorescent readouts to measure cell expansion, apoptosis, and lethality, could be utilized effortlessly in a high throughput screen situation Other systems, for example, quantitative polymerase chain reaction and fluorescence-enacted cell sorting, might be performed at a low to medium throughput screening level and offer wide endpoint measures, for example, measuring cell cycle and burgeoning, and in addition quantifying articulation of biomarkers at the RNA or protein level. Strategies, for example, microarrays, chip-sequencing, single cell illumina-based sequencing, and proteomic methodologies, e.g., affinity column purification and matrix assisted laser desorption ionization time-of-flight mass spectrometry, might be utilized successfully as a high-end investigation for target identification and characterization of the lead compound(Anzalone et al,2010).

**Provisions of stem cells in medication finding**

One of the clear requisitions of stem cells lies in clearing up disease mechanism and harmfulness (Guzman et al, 2005). Testing lead mixes for neuronal, hepatic, and cardiovascular toxicity might give immediate evaluation of the impacts and symptoms of medicines. Embryonic or tissue-particular stem cell from ordinary human and sick patients might be gotten and separated in neurons, hepatocytes, or cardiomyocytes for poisonous quality testing (Croker et al, 2008). In a situation where stem cells are not accessible, substantial cells from typical human or unhealthy patients could be reprogrammed into impelled pluripotent stem cell for further separation and lethality testing. Notwithstanding, it must be noted that the complete atomic nature of affected pluripotent stem cell has not been completely assessed, subsequently run clinical interpretation of any screen done on instigated pluripotent stem cells won't be conceivable within a brief span of time. In neurodegenerative conditions like Parkinson's malady, stroke, Alzheimer's infection, and Huntington's illness, stem cell based medicine revelation projects will convert the path in which treatments are found and outlined (Greenberger et al, 2000).

Screens pointed at enhancing stem cell populaces or controlling their separation into a specific cell sort might be massively useful in quicker recuperation from malady (Plowman et al,1999). At present, different screens to detach lead atoms fit for expanding the expansion of stem cell, while protecting their "stem-like" properties and screens pointed at coordinated separation of stem cells are continuously performed in vitro. The latest advancement of engineering that permits the reprogramming of substantial cells into instigated pluripotent stem cells shows an open door to direct screens on actuated pluripotent stem cell inferred from patients with the point of discovering lead atoms that postpone the onset of infection, accelerate the recuperation methodology, or conceivably cure the sickness(Kitambi et al,2009). Stem cell or actuated pluripotent stem cells could additionally go about as transport operators for conveyance of little particles, remedial executors, or the right form of an unhealthy gene in patients. Screens pointed at cancer stem cell might help us in planning better treatment, as well as empower disclosure of molecules that could bring about a long haul ailment free state. It is exceptionally sensible to envision making typical or ailment particular human stem cell boards to help in deliberations for screening, discovery, and advancement of medications.

**Conclusion**

All in all, stem cells (both typical and malignant) are an important apparatus in the medication disclosure process. They empower quick recognizable proof of remedially helpful molecule that can adjust ordinary and tumorigenic stem cell conduct. In spite of the fact that the immediate clinical requisitions of human embryonic stem cell are constrained because of moral concerns and the potential for teratoma arrangement, they can in any case be intensely misused as an apparatus in different high substance screens steered towards reviving toward oneself, multipotency, and separation. The recognizable proof of tissue-particular stem cells, cancer stem cell, and the latest improvement of affected pluripotent stem cells, offers an engaging open door for creating medicine screens pointed at different human malady states. Medication screens and stem cell examination can possibly create novel cellular and gene therapies that could be specifically connected in the clinical medicine of different hereditary and degenerative disease.

**Acknowledgement:**

**Conflicts of Interest Statement:**

The Authors declare no conflicts of interest.

## References

1. Dhawan J, Rando TA. Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell quiescence, activation and replenishment. *Trends Cell Biol*. 2005;15(12):666–673.
2. Mimeault M, Batra SK. Concise review: recent advances on the sig- nificance of stem cells in tissue regeneration and cancer therapies. *Stem Cells*. 2006;24(11):2319–2345.
3. Abdallah BM, Kassem M. The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. *J Cell Physiol*. 2009;218(1):9–12.
4. Laustriat D, Gide J, Peschanski M. Human pluripotent stem cells in drug discovery and predictive toxicology. *Biochem Soc Trans*. 2010;38(4):1051–1057.
5. Danovi D, Falk A, Humphreys P, et al. Imaging-based chemical screens using normal and glioma-derived neural stem cells. *Biochem Soc Trans*.2010;38(4):1067–1071.
6. Tremblay PL, Berthod F, Germain L, Auger FA. In vitro evaluation of the angiostatic potential of drugs using an endothelialized tissue-engineered connective tissue. *J Pharmacol Exp Ther*. 2005;315(2):510–516.
7. Nirmalanandhan VS, Sittampalam GS. Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges. *J Biomol Screen*. 2009;14(7):755–768.
8. Greenberger JS, Goff JP, Bush J, et al. Expansion of hematopoietic stem cells in vitro as a model system for human tissue engineering. *Orthop Clin North Am*. 2000;31(3):499–510.
9. Bahadduri PM, Polli JE, Swaan PW, Ekins S. Targeting dr ug transporters – combining in silico and in vitro approaches to predict in vivo. *Methods Mol Biol*. 2010;637:65–103.
10. Ishizaki T. Strategic proposals to avoid drug interactions during drug development: a lesson from a terfenadine-related drug interaction. *J Toxicol Sci*. 1996;21(5):301–303.
11. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells – basic and clinical implications for novel cell-based therapies. *Stem Cells*. 2007;25(4):818–827.
12. Smith KA, Rex EB, Komuniecki RW. Are Caenorhabditis elegans recep- tors useful targets for drug discovery: pharmacological comparison of tyramine receptors with high identity from C. elegans (TYRA-2) and Brugia malayi (Bm4). *Mol Biochem Parasitol*. 2007;154(1):52–61.
13. Link EM, Hardiman G, Sluder AE, Johnson CD, Liu LX. Therapeutic target discovery using Caenorhabditis elegans. *Pharmacogenomics*.2000;1(2):203–217.
14. Plowman GD, Sudarsanam S, Bingham J, Whyte D, Hunter T. The protein kinases of Caenorhabditis elegans: a model for signal transduc- tion in multicellular cells. *Proc Natl Acad Sci U S A*.1999;96(24):13603–13610.
15. Tickoo S, Russell S. Drosophila melanogaster as a model system for drug discovery and pathway screening. *Curr Opin Pharmacol*. 2002;2(5):555–560.
16. Gunawardena S, Her LS, Brusch RG, et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. *Neuron*. 2003;40(1):25–40.
17. Bujan J, Pascual G, Corrales C, Gomez-Gil V, Garcia-Honduvilla N, Bellon JM. Muscle-derived stem cells used to treat skin defects prevent wound contraction and expedite reepithelialization. *Wound Repair Regen*. 2006;14(2):216–223.
18. Chia NY, Chan YS, Feng B, et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. *Nature*. 2010;468(7321):316–320.
19. Jiang SQ, Paulus H. A high-throughput, homogeneous, fluorescence polarization assay for inhibitors of hedgehog protein autoprocessing. *J Biomol Screen*. 2010;15(9):1082–1087.
20. Lang DA, Hadley DM, Teasdale GM, Macpherson P, Teasdale E.Gadolinium-DTPA enhanced magnetic resonance imaging in human head injury. *Acta Neurochir (Wien)*. 1990;51:293–295.
21. Thorne CA, Hanson AJ, Schneider J, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. *Nat Chem Biol*. 2010;6(11):829–836.

22. Jozefczuk J, Prigione A, Chavez L, Adjaye J. Comparative analysis of human embryonic stem cell and induced pluripotent stem cell- derived hepatocyte-like cells reveals current drawbacks and possible strategies for improved differentiation. *Stem Cells Dev*. 2011;20(7):1259–1275.

23. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. *Pharm Res*. 2007;24(5):819–841.

24. Anzalone R, Lo Iacono M, Corrao S, et al. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. *Stem Cells Dev*.2010;19(4):423–438.

25. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. *J Cell Mol Med*. 2008;12(2):374–390.

26. Giacomotto J, Segalat L. High-throughput screening and small animal models, where are we? *Br J Pharmacol*. 2010;160(2):204–216.

27. Gosai SJ, Kwak JH, Luke CJ, et al. Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin alpha1-antitrypsin Z. *PloS One*. 2010;5(11):e15460.

28. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knock- outs model pipeline drugs of the pharmaceutical industry. *Curr Opin Pharmacol*. 2003;3(5):563–570.Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. *Cell*. 2010;142(1):39–51.

29. Yamazaki H, Nishida H, Iwata S, Dang NH, Morimoto C. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. *Biochem Biophys Res Commun*. 2009;383(2):172–177.

30. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood*. 2005;105(11):4163–4169.

31. Amore BM, Gibbs JP, Emery MG. Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. *Comb Chem High Throughput Screen*. 2010;13(2):207–218.

32. LeBaron MJ, Rasoulpour RJ, Klapacz J, Ellis-Hutchings RG, Hollnagel HM, Gollapudi BB. Epigenetics and chemical safety assessment. *Mutat Res*. 2010;705(2):83–95.

33. Kitambi SS, McCulloch KJ, Peterson RT, Malicki JJ. Small molecule screen for compounds that affect vascular development in the zebrafish retina. *Mech Dev*. 2009;126(5–6):464–477.

34. Biechele TL, Camp ND, Fass DM, et al. Chemical-genetic screen identi- fies riluzole as an enhancer of Wnt/beta-catenin signaling in melanoma. *Chem Biol*. 2010;17(11):1177–1182.